$907 Million is the total value of Cormorant Asset Management, LP's 84 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLVS | New | CLOVIS ONCOLOGY INC | $23,433,000 | – | 650,000 | +100.0% | 2.58% | – |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $16,904,000 | – | 800,000 | +100.0% | 1.86% | – |
| GEMP | New | GEMPHIRE THERAPEUTICS INC | $9,828,000 | – | 900,000 | +100.0% | 1.08% | – |
| BOLD | New | AUDENTES THERAPEUTICS INC | $8,008,000 | – | 449,660 | +100.0% | 0.88% | – |
| EBS | New | EMERGENT BIOSOLUTIONS INC | $7,883,000 | – | 250,000 | +100.0% | 0.87% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $7,763,000 | – | 1,150,000 | +100.0% | 0.86% | – |
| FLGT | New | FULGENT GENETICS INC | $7,376,000 | – | 800,000 | +100.0% | 0.81% | – |
| AVXS | New | AVEXIS INC | $5,434,000 | – | 131,858 | +100.0% | 0.60% | – |
| CATB | New | CATABASIS PHARMACEUTICALS IN | $4,928,000 | – | 800,000 | +100.0% | 0.54% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $4,241,000 | – | 1,155,600 | +100.0% | 0.47% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.